Lipocine Inc. (NASDAQ: LPCN) has announced an exclusive supply and distribution agreement with Pharmalink to commercialize TLANDO®, its oral testosterone replacement therapy, in the Gulf Cooperation Council (GCC) countries. The agreement covers Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, Bahrain, and Oman.
Under the terms of the agreement, Lipocine received an upfront payment from Pharmalink. Upon obtaining Marketing Authorizations in individual GCC countries, Lipocine will provide TLANDO drug product to Pharmalink at an agreed transfer price. Pharmalink will have exclusive rights to TLANDO in the GCC region and will be responsible for promotion, distribution, and sale of the product in the territory.
This partnership aligns with Lipocine's global strategy to expand the availability of TLANDO and make it broadly accessible. Pharmalink's expertise and established network in the GCC region make them an ideal partner to support the adoption and growth of TLANDO in these markets.